Peptide research profile
Tirzepatide
Also known as Mounjaro · tirz · Zepbound
SURMOUNT-1 demonstrated substantial sustained weight reduction in adults with obesity or overweight plus a weight-related complication. The Zepbound label also includes moderate-to-severe obstructive sleep apnea in adults with obesity.
High evidenceFDA approved
- Evidence maturity
- Established record
- Regulatory status
- FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 2
- Side-effect records
- 1,289Named most often: Nausea · Constipation · Alopecia
Educational. Not medical advice.
Summary
A dual GIP and GLP-1 receptor agonist with FDA-approved products for specific metabolic indications.
What is Tirzepatide being studied for?
Weight management and obesity-related sleep apnea
How is it thought to work?
Activates GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, appetite, caloric intake, and gastric emptying.
Recorded outcomes
1,289 side-effect records on Tirzepatide
Free account3 graded outcomes and 2 sources for Tirzepatide.
Outcome table and every source open with a free account. No card.
Update history
Updated
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.